AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer
A histology-based artificial intelligence (AI) biomarker may help personalize adjuvant chemotherapy selection for patients with resected pancreatic ductal adenocarcinoma, according to the results of a study by Beaufils et al. The investigators developed and validated a deep learning model that analyzes routine histology slides to predict the relative benefit of adjuvant gemcitabine vs modified FOLFIRINOX (mFOLFIRINOX). The resulting biomarker, termed PANCprAId, identified patient subgroups with differential benefit from the two regimens in an external validation cohort from the randomized phase III PRODIGE-24/CCTG PA6 trial. The study is published in the Journal of Clinical Oncology.
NIH-Funded International Research Yields Patient-Derived Tumor Compendium
A research project funded by the National Institutes of Health (NIH), with collaborators around the country and the world, has generated extensive and diverse collections of patient-derived tumor models. Tumor tissue from patients with cancer contributed to the compendium of tumor models that will enhance the study of tumor biology and be an asset in accelerating the development of cancer therapies, while guiding future research directions.
Stanford Appoints New Leader to Expand Impact in Early Drug Development
Pamela Munster, MD, joined the Stanford Cancer Institute as the inaugural Associate Director for Early Detection and Interception Research on August 1, 2026. She also assumed a faculty appointment as a Professor in the Stanford Medicine Division of Oncology.
First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer
In a phase Ib study published in the Journal of Clinical Oncology, Zhao et al found that the first-in-class bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren, BL-B01D1) demonstrated antitumor activity in patients with relapsed extensive-stage small cell lung cancer, particularly when used as second-line therapy.
Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care
Above 80% of cancer care providers globally report a lack of knowledge regarding integrative oncology treatments that prevent them from offering these services to patients, according to survey findings published in Supportive Care in Cancer.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed/Refractory CLL in the Post-cBTKi SettingMore Top Stories
Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth
Maura L. Gillison, MD, PhD Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything about her as a scientist, a clinician, and a person. She was direct...
AASLD Publishes Landmark North American Framework to Advance Treatment Decisions for HCC
The American Association for the Study of Liver Diseases (AASLD) recently announced the publication of BEACON-HCC, a landmark multidisciplinary consensus now available online in HEPATOLOGY. The consensus was developed by 20 North American experts representing hepatology, medical oncology, surgery,...
ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
A panel of ASCO experts voted to approve ASCO’s first guideline on ctDNA testing in patients with solid tumors or lymphoma on November 18, 2025.1 The guideline addresses four overarching clinical questions: when ctDNA testing should (or should not) be used to (1) support cancer diagnosis; (2)...
The Fear of Having Cancer Never Goes Away
There is a strong history of breast cancer in my family, and the fact that I have dense breasts adding to my risk of developing the disease, kept me vigilant about getting a yearly mammogram screening since I turned 32. The test never showed any suspicious lesions over the last nearly 2 decades,...
Adding Irinotecan to Preoperative Chemoradiotherapy Does Not Improve Outcomes in Locally Advanced Rectal Cancer
In the phase III ARISTOTLE trial, adding irinotecan to preoperative capecitabine-based chemoradiotherapy did not improve disease-free survival in patients with locally advanced rectal cancer, and was also associated with substantially more severe toxicity. The findings were reported by...
Electronic Prior Authorization Requirements for Drugs
The Association for Clinical Oncology (ASCO) submitted formal comments (see https://bit.ly/4xYRg1j) to the Centers for Medicare & Medicaid Services (CMS) in response to the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule. If finalized, this rule will require...
Early Intravesical Pirarubicin Improves Relapse-Free Survival in Upper Tract Urothelial Carcinoma
A single intravesical dose of the antracycline pirarubicin administered within 24 hours after radical nephroureterectomy significantly improved relapse-free survival in patients with upper tract urothelial carcinoma. The benefit was driven mainly by fewer new bladder tumors after surgery, while...
